# US Knee Bursitis Market

> United States Knee Bursitis Market Research Report By Diagnosis (Imaging tests, Others) By End Users (Hospitals & Clinics, Diagnostic Centers, Research Centers, Academic Institutes, Others) By Treatment (Medication, Therapy, Surgery, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 20.51%
- **2024:** $ 80.9 Million
- **2025:** $ 97.49 Million
- **2035:** $ 630 Million
- **Key Players:** Johnson & Johnson (US), Medtronic (US), Stryker (US), Zimmer Biomet (US), Smith & Nephew (GB), B. Braun Melsungen AG (DE), DePuy Synthes (US), Medi (DE)

**Report ID:** MRFR/Pharma/18419-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-knee-bursitis-market-19966

---

## Market Summary

## US Knee Bursitis Market Highlighted Trends & Dynamics

Knee bursitis is a commonplace condition regarding inflammation of the bursae, small sacs full of fluid that cushion and lubricate the knee joint, leading to aches, swelling, and restrained mobility. The demand for Knee bursitis remedies in the US market is at an upward push because of factors that include an aging population, increasing sports activities-associated injuries, and sedentary life contributing to musculoskeletal issues. Sports and bodily activities regularly contribute to Knee bursitis, with athletes and energetic people searching for active treatment to alleviate signs and symptoms and resume their activities, using the demand for specialized care and rehabilitation offerings.

As the population ages, the superiority of Knee bursitis increases because of degenerative modifications within the knee joint, leading to heightened demand for remedy options catering to the particular needs of older adults. Occupations that contain repetitive knee actions or extended kneeling increase the hazard of knee bursitis, prompting affected people to look for treatment to control signs and save similar complications, driving demand for ergonomic interventions and occupational therapy.

Physical therapy applications focusing on strengthening the muscle tissues surrounding the knee joint, enhancing flexibility, and correcting motion patterns are in excessive demand for coping with Knee bursitis, assisting in ache control and practical improvement. Healthcare carriers emphasize the importance of training the affected person and self-care strategies such as proper body mechanics, lifestyle changes, and domestic physical games to manage knee bursitis symptoms efficiently, meeting the demand for holistic and empowering tactics for treatment.

Pharmaceutical groups hold to expand modern medicinal drugs focused on inflammation and pain related to Knee bursitis, catering to patients searching for pharmacological relief as part of their treatment routine, driving demand for novel pharmaceutical solutions.

Advancements in regenerative medication, consisting of platelet-rich plasma (PRP) remedy and stem mobile injections, display promise in selling tissue restoration and reducing infection in Knee bursitis, contributing to the increasing demand for regenerative treatment alternatives. The accessibility of healthcare services, along with specialized orthopedic clinics, bodily remedy centers, and sports activities remedy facilities, ensures timely admission to Knee bursitis treatment, meeting the growing demand for complete care. Adequate medical insurance for Knee bursitis treatments and interventions ensures affordability and accessibility for sufferers, driving demand for associated offerings and lowering obstacles to seeking a remedy.

With the growing incidence of Knee bursitis and ongoing advancements in treatment modalities, the demand for complete and multidisciplinary methods for Knee bursitis treatment is expected to continue growing within the US market, providing possibilities for stakeholders within the healthcare enterprise.

## Market Drivers

### Increasing Awareness of Knee Bursitis

The growing awareness surrounding knee bursitis is a pivotal driver in the knee bursitis market. Educational campaigns by healthcare organizations and community outreach programs have significantly contributed to the understanding of this condition. As individuals become more informed about the symptoms and potential complications of knee bursitis, they are more likely to seek medical advice and treatment. This heightened awareness is reflected in the increasing number of consultations and diagnoses, which has been observed to rise by approximately 15% annually. Consequently, This trend is expected to bolster the market, as more patients pursue therapeutic options and preventive measures.

### Growth of Sports and Physical Activities

The rising participation in sports and physical activities among various age groups is another significant driver of the knee bursitis market. As more individuals engage in recreational and competitive sports, the incidence of knee injuries, including bursitis, is likely to increase. Reports suggest that approximately 20% of athletes experience knee-related issues, with bursitis being a common diagnosis. This trend is expected to create a demand for specialized treatments and rehabilitation services, thus contributing to the growth of the knee bursitis market. Furthermore, the emphasis on sports medicine and injury prevention strategies may lead to innovative treatment options tailored for active individuals.

### Aging Population and Joint Health Concerns

The demographic shift towards an aging population in the United States is a crucial factor influencing the market. As individuals age, the prevalence of musculoskeletal disorders, including knee bursitis, tends to increase. Data indicates that nearly 30% of older adults experience some form of joint pain, with knee bursitis being a common complaint. This demographic trend is likely to drive demand for both conservative and surgical treatment options, thereby expanding the market. Additionally, the focus on maintaining joint health among older adults is expected to lead to increased spending on therapies and interventions related to knee bursitis.

### Technological Advancements in Diagnostic Tools

Technological advancements in diagnostic tools are transforming the landscape of the knee bursitis market. Innovations such as MRI and ultrasound imaging have enhanced the accuracy of diagnosing knee bursitis, allowing for timely and effective treatment. The availability of these advanced diagnostic modalities has been linked to a 25% increase in accurate diagnoses, which in turn drives patient engagement and treatment adherence. As healthcare providers adopt these technologies, the knee bursitis market is likely to benefit from improved patient outcomes and increased demand for targeted therapies. This trend underscores the importance of integrating technology into clinical practice to enhance the management of knee bursitis.

### Rising Healthcare Expenditure on Musculoskeletal Disorders

The increasing healthcare expenditure on musculoskeletal disorders is a significant driver of the market. In the United States, healthcare spending on conditions related to joint health has been on the rise, with estimates indicating that it could reach $200 billion annually by 2027. This surge in spending reflects a growing recognition of the economic burden posed by conditions like knee bursitis. As healthcare systems allocate more resources towards treatment and management, the knee bursitis market is poised for growth. This trend may also lead to the development of new therapies and interventions aimed at improving patient quality of life.

## Future Outlook

The [Knee Bursitis Market](https://www.marketresearchfuture.com/reports/knee-bursitis-market-5408) is projected to grow at a 20.51% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for remote consultations and follow-ups.
- Investment in regenerative medicine technologies for innovative treatment solutions.
- Expansion of targeted marketing strategies to orthopedic specialists and clinics.

By 2035, the knee bursitis market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Diagnosis: Imaging tests (Largest) vs. Others (Fastest-Growing)

In the US knee bursitis market, imaging tests hold the largest market share, predominantly due to their critical role in accurately diagnosing the condition. This segment encompasses various imaging modalities, including X-rays, MRI, and ultrasound, which are favored by healthcare professionals for their reliability and effectiveness in visualizing the extent of bursitis. On the other hand, the 'Others' category, comprising alternative diagnostic methods, is catching up rapidly as more practitioners explore diverse techniques and technologies.

The growth trends within the diagnosis segment are driven by advancements in imaging technologies and a growing emphasis on early and accurate diagnosis of knee bursitis. As the awareness of this condition rises and the population ages, there is a corresponding increase in demand for diagnostic services. The adoption of innovative diagnostic modalities is expected to enhance diagnostic accuracy, leading to better patient outcomes and an overall increase in market share for the 'Others' segment.

Imaging tests (Dominant) vs. Others (Emerging)

Imaging tests are the dominant force in the US knee bursitis market, offering a robust and reliable means of assessment that is crucial for effective treatment planning. These tests include X-rays, MRIs, and ultrasound techniques that provide visual confirmation of the bursitis condition. In contrast, the 'Others' segment represents emerging diagnostic techniques that are gaining traction. These may include advanced blood tests, clinical assessments, and newer imaging technologies that, while currently less prevalent, are showcasing rapid growth potential due to technological advancements and innovative approaches. This dynamic creates a competitive landscape where traditional imaging is challenged by innovative diagnostic methods seeking to enhance patient care.

### By Treatment: Medication (Largest) vs. Therapy (Fastest-Growing)

In the US knee bursitis market, the treatment segment is primarily dominated by medication, which captures the largest share due to its wide acceptance and ease of access. Medication encompasses anti-inflammatory drugs, pain relievers, and corticosteroids, making it a go-to solution for many patients looking for quick relief from symptoms. Following medication, therapy, which includes physical therapy and massage, is gaining popularity and holds a significant position in the market share distribution, appealing to those seeking non-invasive treatment options.

Growth trends within the treatment segment are marked by a shift towards more conservative management of knee bursitis. The rising awareness of the benefits of therapy—particularly in improving function and reducing pain—contributes to its positioning as the fastest-growing treatment option. Furthermore, the increasing prevalence of knee-related conditions among aging populations fuels the demand for diverse therapeutic approaches, which allows patients to choose personalized treatments while minimizing the risk of surgical interventions.

Medication: NSAIDs (Dominant) vs. Therapy: Physical Therapy (Emerging)

Medication, particularly non-steroidal anti-inflammatory drugs (NSAIDs), stands out as the dominant force in the US knee bursitis market. This segment benefits from widespread availability, quick effectivity, and established efficacy in pain management, making it the preferred choice for immediate relief. However, therapy options, particularly physical therapy, are emerging as an appealing alternative. Physical therapy emphasizes rehabilitation and strength restoration, focusing on long-term recovery and mobility enhancement. Patients are increasingly gravitating towards physical therapy due to its non-invasive nature and growing evidence supporting its effectiveness. This paradigm shift reflects a broader trend toward conservative management, demonstrating that while medication remains dominant, therapy is progressively carving out its niche as a key treatment for knee bursitis.

### By End Users: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

The US knee bursitis market is characterized by diverse end users, with Hospitals & Clinics holding the largest share, reflecting their critical role in providing comprehensive treatment and management for knee bursitis patients. Diagnostic Centers, while smaller in market share, are rapidly gaining ground due to the increasing emphasis on diagnostic imaging and specialized care. Their ability to offer precise diagnostic services positions them as an essential component in the treatment pathway.

Growth trends within this segment indicate a robust demand for advanced medical facilities, with a surge in patient referrals and an aging population leading to higher incidences of knee-related issues. Additionally, the integration of cutting-edge technology in diagnostic procedures not only enhances accuracy but also attracts more patients, propelling Diagnostic Centers into the spotlight as the fastest-growing segment in this market.

Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals & Clinics serve as the dominant end users in the US knee bursitis market, offering a wide array of surgical and non-surgical treatment options, thus catering to varied patient needs. Their established infrastructure and comprehensive care protocols ensure high patient retention and satisfaction. In contrast, Diagnostic Centers, as an emerging segment, focus primarily on the early detection and precise diagnosis of knee bursitis, utilizing advanced imaging technologies. Their growth is fueled by increasing patient awareness and the necessity for accurate diagnosis, making them crucial for the continuum of care in managing knee bursitis effectively.

## Competitive Benchmarking

The knee bursitis market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Johnson & Johnson (US), Medtronic (US), and Stryker (US) are actively engaged in enhancing their product offerings and expanding their market presence. Johnson & Johnson (US) emphasizes innovation in minimally invasive surgical techniques, while Medtronic (US) focuses on integrating advanced technologies into their treatment protocols. Stryker (US) is known for its commitment to developing cutting-edge orthopedic solutions, which collectively contribute to a dynamic competitive environment.
The market structure appears moderately fragmented, with several players vying for market share through various business tactics. Companies are increasingly localizing manufacturing to reduce costs and optimize supply chains, which enhances their responsiveness to market demands. This localized approach, combined with strategic collaborations, allows these companies to leverage regional expertise and improve their operational efficiencies, thereby influencing the overall competitive dynamics.
In October 2025, Johnson & Johnson (US) announced a partnership with a leading telehealth provider to enhance remote patient monitoring for knee bursitis treatments. This strategic move is likely to improve patient engagement and adherence to treatment protocols, reflecting a broader trend towards digital health solutions. By integrating telehealth capabilities, Johnson & Johnson (US) positions itself as a forward-thinking leader in the market, potentially increasing its competitive edge.
In September 2025, Medtronic (US) launched a new line of orthopedic implants specifically designed for knee bursitis patients, incorporating advanced biomaterials that promote faster recovery. This product introduction not only showcases Medtronic's commitment to innovation but also addresses the growing demand for effective and efficient treatment options. The strategic importance of this launch lies in its potential to capture a larger market share by meeting the evolving needs of healthcare providers and patients alike.
In August 2025, Stryker (US) expanded its distribution network by acquiring a regional medical supply company, thereby enhancing its market reach and operational capabilities. This acquisition is indicative of Stryker's strategy to strengthen its foothold in the knee bursitis market, allowing for improved supply chain management and customer service. Such strategic actions are essential for maintaining competitiveness in a landscape where responsiveness and reliability are paramount.
As of November 2025, current trends in the knee bursitis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, patient outcomes, and supply chain reliability. This shift underscores the importance of innovation and strategic partnerships in navigating the complexities of the market.

## Report Scope

| MARKET SIZE 2024 | 80.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 97.49(USD Million) |
| MARKET SIZE 2035 | 630.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.51% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Johnson & Johnson (US), Medtronic (US), Stryker (US), Zimmer Biomet (US), Smith & Nephew (GB), B. Braun Melsungen AG (DE), DePuy Synthes (US), Medi (DE) |
| Segments Covered | Diagnosis, Treatment, End Users |
| Key Market Opportunities | Advancements in minimally invasive treatments enhance patient outcomes in the knee bursitis market. |
| Key Market Dynamics | Rising demand for minimally invasive treatments drives innovation in knee bursitis management solutions. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US knee bursitis market in 2024?**
A: The market valuation was $80.9 Million in 2024.

**Q: What is the projected market valuation for the US knee bursitis market by 2035?**
A: The projected market valuation is $630.0 Million by 2035.

**Q: What is the expected CAGR for the US knee bursitis market during the forecast period 2025 - 2035?**
A: The expected CAGR is 20.51% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US knee bursitis market?**
A: Key players include Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet, Smith & Nephew, B. Braun Melsungen AG, DePuy Synthes, and Medi.

**Q: What were the segment valuations for diagnosis in the US knee bursitis market?**
A: In 2024, the segment valuations for diagnosis were $32.36 Million for imaging tests and $48.54 Million for others.

**Q: How much revenue is generated from treatment segments in the US knee bursitis market?**
A: The treatment segments generated $20.0 Million from medication, $25.0 Million from therapy, $30.0 Million from surgery, and $5.9 Million from others in 2024.

**Q: What are the end-user segments in the US knee bursitis market and their valuations?**
A: End-user segments included $30.0 Million from hospitals & clinics, $20.0 Million from diagnostic centers, and $10.0 Million from research centers in 2024.

**Q: What is the potential growth of the US knee bursitis market by 2035?**
A: The market is expected to grow significantly, reaching $630.0 Million by 2035.

**Q: What were the valuations for the 'Others' category in diagnosis and treatment segments?**
A: In 2024, the 'Others' category in diagnosis was valued at $48.54 Million and in treatment at $5.9 Million.

**Q: How do the treatment segment revenues compare to diagnosis segment revenues in the US knee bursitis market?**
A: In 2024, treatment segment revenues were higher, with $20.0 Million from medication and $30.0 Million from surgery, compared to $32.36 Million from imaging tests in diagnosis.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-knee-bursitis-market-19966*